Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Agennix AG Issues FY 2013 Revenue Guidance Below Analysts' Estimates
Agennix AG announced that no revenues are expected to be generated during fiscal year 2013. According to I/B/E/S estimates, analysts on average are expecting the Company to report for fiscal year 2013 revenue of EUR 20 million.
Latest Key Developments in Biotechnology
- Rockwell Medical Inc Closes $40.3 Million Public Offering Of Common Stock
- Rockwell Medical Inc Announces PRIME Study Results At The 50th ERA-EDTA Meeting In Istanbul
- Intercept Pharmaceuticals Inc Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
- Synageva BioPharma Corp's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from U.S. Food and Drug Administration
- Share this
- Link this
- Digg this
Follow Reuters